Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas

Neurosurg Rev. 2022 Apr;45(2):1401-1411. doi: 10.1007/s10143-021-01662-7. Epub 2021 Oct 4.

Abstract

A subset of large non-functioning pituitary adenomas (lNFPA) and giant non-functioning pituitary adenomas (gNFPA) undergoes early progression/recurrence (P/R) after surgery. This study revealed the clinical and image predictors of P/R in lNFPA and gNFPA, with emphasis on solid tumor size. This retrospective study investigated the preoperative MR imaging features for the prediction of P/R in lNFPA (> 3 cm) and gNFPA (> 4 cm). Only the patients with a complete preoperative brain MRI and undergone postoperative MRI follow-ups for more than 1 year were included. From November 2010 to December 2020, a total of 34 patients diagnosed with lNFPA and gNFPA were included (median follow-up time 47.6 months) in this study. A total of twenty-three (23/34, 67.6%) patients had P/R, and the median time to P/R is 25.2 months. Solid tumor diameter (STD), solid tumor volume (STV), and extent of resection are associated with P/R (p < 0.05). Multivariate analysis showed large STV is a risk factor for P/R (p < 0.05) with a hazard ratio of 30.79. The cutoff points of STD and STV for prediction of P/R are 26 mm and 7.6 cm3, with AUCs of 0.78 and 0.79 respectively. Kaplan-Meier analysis of tumor P/R trends showed that patients with larger STD and STV exhibited shorter progression-free survival (p < 0.05). For lNFPA and gNFPA, preoperative STD and STV are significant predictors of P/R. The results offer objective and valuable information for treatment planning in this subgroup.

Keywords: MRI; Non-functioning; Pituitary macroadenoma; Recurrence; Solid tumor size.

MeSH terms

  • Adenoma* / diagnostic imaging
  • Adenoma* / pathology
  • Adenoma* / surgery
  • Follow-Up Studies
  • Humans
  • Magnetic Resonance Imaging
  • Neoplasm Recurrence, Local / surgery
  • Neurosurgical Procedures / methods
  • Pituitary Neoplasms* / diagnostic imaging
  • Pituitary Neoplasms* / pathology
  • Pituitary Neoplasms* / surgery
  • Retrospective Studies
  • Treatment Outcome